Marché du traitement du lymphœdème en Asie-Pacifique, par type de traitement (thérapie par compression, chirurgie, pharmacothérapie, thérapie au laser et autres), type (lymphœdème primaire et lymphœdème secondaire), zone affectée (génitale, membre inférieur, membre supérieur et autres), groupe d'âge (adulte et gériatrique), voie d'administration (orale, injectable et autres), utilisateur final (hôpitaux, centres de chirurgie ambulatoire, cliniques spécialisées et autres), canal de distribution (appel d'offres direct, pharmacies et autres), pays (Japon, Chine, Inde, Corée du Sud, Australie, Singapour, Thaïlande, Malaisie, Indonésie, Philippines, Vietnam et reste de l'Asie-Pacifique) Tendances et prévisions de l'industrie jusqu'en 2029
Analyse et perspectives du marché : marché du traitement du lymphœdème en Asie-Pacifique
Le marché du traitement du lymphœdème en Asie-Pacifique devrait connaître une croissance significative au cours de la période de prévision de 2022 à 2029. Data Bridge Market Research analyse que le marché du traitement du lymphœdème en Asie-Pacifique croît avec un TCAC de 11,4 % au cours de la période de prévision de 2022 à 2029 et devrait atteindre 239,13 millions USD d'ici 2029 contre 102,69 millions USD en 2022. L'augmentation des dépenses de santé et l'escalade de l'innovation et des technologies sont des moteurs qui devraient favoriser la croissance du marché au cours de la période de prévision.
Le lymphœdème désigne un gonflement qui se produit généralement au niveau des membres supérieurs et inférieurs. Parfois, les deux bras et les deux jambes gonflent. Le lymphœdème est le plus souvent causé par l'ablation ou la destruction de ganglions lymphatiques dans le cadre d'un traitement contre le cancer. Il résulte d'un blocage du système lymphatique, qui fait partie du système immunitaire. Il résulte d'un système lymphatique endommagé et peut entraîner des infections, une défiguration, des douleurs invalidantes et une invalidité. Il n'existe pas de remède contre le lymphœdème.
Le traitement du lymphœdème implique plusieurs thérapies au lieu du traitement standard, car les patients ne sont pas satisfaits ou ne guérissent pas avec le traitement conventionnel du lymphœdème. Ils se tournent vers le traitement alternatif qui offre plus de contrôle sur les décisions de soins de santé et les alternatives s'avèrent plus compatibles avec le système de santé du patient.
Le lymphœdème peut survenir après tout cancer ou son traitement qui affecte le drainage des ganglions lymphatiques. Il peut survenir quelques jours et jusqu'à 30 ans après le traitement du cancer du sein. Les traitements initiaux du lymphœdème sont, entre autres, des thérapies , des interventions chirurgicales et une greffe lympho-veineuse. Mais il n'existe pas de traitement permanent contre le lymphœdème.
A growing number of people are affected with lymphedema which demand highly effective and advanced treatment to minimize the risk during the treatment. The healthcare systems need highly advanced therapies for numerous lymphedema disorders during the treatment of patients. Therefore, the major market players are highly focusing on product launches and product approvals. Additionally, the government and regulatory bodies are supporting market players by virtue of product approval.
The demand for lymphedema treatment has rapidly increased all over the world during the past decade due to the increased incidence of lymphedema patients.
High cost of treatment and adverse side-effects associated with treatment are anticipated to hinder market growth in the projected period.
Strategic initiatives by the market players, increasing healthcare expenditure, soaring number of drugs manufacturers act as an opportunity for this market and is expected to impel the market growth.
It is expected that no permanent cure for lymphedema is the major key challenge for the future growth of Asia-Pacific lymphedema treatment market.
Asia-Pacific lymphedema treatment market report provides details of market share, new developments, and product pipeline analysis, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the market scenario contact us for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.
Asia-Pacific Lymphedema Treatment Market and Market Size
Asia-Pacific lymphedema treatment market is segmented on the basis of treatment type, by type, by affected area, by age group, by route of administration, by end user, by distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
- On the basis of treatment type, Asia-Pacific lymphedema treatment market is segmented in compression therapy, surgery, drug therapy, laser therapy and others. In 2022, compression therapy segment is expected to dominate the market due to public-private collaborations in drug and medical devices development.
- On the basis of type, Asia-Pacific lymphedema treatment market is segmented in primary lymphedema and secondary lymphedema. In 2022, secondary lymphedema segment is expected to dominate the market due to rise in number of lymphedema patients globally.
- On the basis of affected area, Asia-Pacific lymphedema treatment market is segmented genital, lower extremity and upper extremity. In 2022, lower extremity segment is expected to dominate the market due to rise in number of therapies conducted for the treatment of lymphedema.
- On the basis of age group, the Asia-Pacific lymphedema treatment market is segmented into adult and geriatric. In 2022, adult segment is expected to dominate the market because of increasing prevalence of lymphedema in adult population.
- On the basis of route of administration, Asia-Pacific lymphedema treatment market is segmented in oral, injectable and others. In 2022, oral segment is expected to dominate the market owing to increased research and development as high prevalence of the disease would lead to increased demand for lymphedema treatment and thus there will be surge in research and development.
- On the basis of end user, Asia-Pacific lymphedema treatment market is segmented in hospitals, ambulatory surgical centres, speciality clinics and others. In 2022, hospitals segment is expected to dominate the market owing to the rising product launches by the key market players.
- On the basis of distribution channel, Asia-Pacific lymphedema treatment market is segmented in direct tender, pharmacy stores and others. In 2022, pharmacy stores segment is expected to dominate the market owing to the rising drug approvals by the government.
Asia-Pacific Lymphedema Treatment Market Country Level Analysis
The Asia-Pacific lymphedema treatment market is analyzed and market size information is provided base, by treatment type, by type, by affected area, by age group, by route of administration, by end user, by distribution channel.
Countries covered in the Asia-Pacific lymphedema treatment market report are China, Argentina, Peru and Rest of South America.
China is expected to dominate the Asia-Pacific lymphedema treatment market due to increasing rising government funding in the region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of Asia-Pacific brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.
Rising healthcare expenditure and escalation in innovations and technologies in the Asia-Pacific lymphedema treatment market are creating new opportunities for players in the Asia-Pacific lymphedema treatment market
Asia-Pacific lymphedema treatment market region segment in the China is expected to grow with the highest rate and it is dominating the region in the forecast period of 2022 to 2029 because of rising government funding.
Le marché du traitement du lymphœdème en Asie-Pacifique vous fournit également une analyse de marché détaillée pour la croissance de chaque pays dans un secteur particulier avec les ventes du marché du traitement du lymphœdème en Asie-Pacifique, l'impact des progrès sur le marché du traitement du lymphœdème en Asie-Pacifique et les changements dans les scénarios réglementaires avec leur soutien au marché du traitement du lymphœdème en Asie-Pacifique.
Analyse du paysage concurrentiel et des parts de marché du traitement du lymphœdème en Asie-Pacifique
Le paysage concurrentiel du marché du traitement du lymphœdème en Asie-Pacifique fournit des détails par concurrent. Les détails inclus sont la présentation de l'entreprise, les finances de l'entreprise, les revenus générés, le potentiel du marché, les investissements dans la recherche et le développement, les nouvelles initiatives du marché, les sites et installations de production, les forces et les faiblesses de l'entreprise, le lancement de produits, les pipelines d'essais de produits, les approbations de produits, les brevets, la largeur et la portée du produit, la domination des applications et la courbe de survie technologique. Les points de données ci-dessus fournis ne concernent que l'orientation des entreprises liée au marché du traitement du lymphœdème en Asie-Pacifique.
Français Les principaux acteurs couverts dans le rapport sont Bio Compression Systems, Inc., Lohmann & Rauscher, Mego Afek ltd, SIGVARIS, Tactile Systems Technology Inc., medi GmbH & Co. KG, Paul Hartmann AG, Sanyleg Srl, 3M, ConvaTec Inc., Julius Zorn GmbH, Cardinal Health, Inc., Smith & Nephew plc, ThermoTek, Huntleigh Healthcare Limited, Herantis Pharma Plc. sont les acteurs du marché du traitement du lymphœdème en Asie-Pacifique. Les analystes de DBMR comprennent les atouts de la concurrence et fournissent une analyse concurrentielle pour chaque concurrent séparément.
De nombreux lancements de produits et accords sont également initiés par les entreprises du monde entier, ce qui accélère encore davantage le marché du traitement du lymphœdème en Asie-Pacifique.
Par exemple,
- En juin 2021, InfuSystem Holdings, Inc. a annoncé avoir conclu un accord conjoint avec Bio Compression Systems, Inc. en vertu duquel InfuSystem ajoutera la thérapie du lymphoedème à ses installations de la plateforme de services de thérapie intégrée (« ITS »). Cela a stimulé les ventes des deux sociétés, contribuant ainsi à la génération de revenus.
- En avril 2020, le groupe L&R renforce sa position sur le marché de la compression - L&R a acquis les actifs de l'expert français en compression MTA. Cette acquisition a permis à L&R d'élargir son portefeuille de produits pour le traitement de l'insuffisance veineuse et du lymphœdème et de renforcer ainsi sa position sur le marché français.
SKU-
Accédez en ligne au rapport sur le premier cloud mondial de veille économique
- Tableau de bord d'analyse de données interactif
- Tableau de bord d'analyse d'entreprise pour les opportunités à fort potentiel de croissance
- Accès d'analyste de recherche pour la personnalisation et les requêtes
- Analyse de la concurrence avec tableau de bord interactif
- Dernières actualités, mises à jour et analyse des tendances
- Exploitez la puissance de l'analyse comparative pour un suivi complet de la concurrence
Table des matières
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF ASIA PACIFIC LYMPHEDEMA TREATMENT MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 PRODUCT TYPE LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 MARKET APPLICATION COVERAGE GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL'S ANALYSIS
4.2 PORTER'S MODEL
5 PIPELINE ANALYSIS FOR ASIA PACIFIC LYMPHEDEMA TREATMENT MARKET
6 EPIDEMIOLOGY
7 REGULATORY GUIDELINES FOR ASIA PACIFIC LYMPHEDEMA TREATMENT MARKET
7.1 U.S.
7.2 EUROPE
7.3 INDIA
7.4 MEXICO
7.5 CANADA
8 MARKET OVERVIEW
8.1 DRIVERS
8.1.1 RISE IN THE NUMBER OF LYMPHEDEMA CASES ASIA PACIFICLY
8.1.2 INCREASE IN THE PREVALENCE OF CANCERS
8.1.3 INCREASING NUMBER OF HEALTHCARE FACILITIES
8.1.4 MULTIPLE THERAPIES
8.2 RESTRAINTS
8.2.1 HIGH COST OF TREATMENT
8.2.2 LACK OF AWARENESS ABOUT THE DISEASE
8.3 OPPORTUNITIES
8.3.1 DRUG APPROVALS
8.3.2 PARTNERSHIP AND AGREEMENT BY MAJOR PLAYERS
8.4 CHALLENGES
8.4.1 NO PERMANENT CURE FOR LYMPHEDEMA
8.4.2 DIFFICULT REIMBURSEMENT
9 IMPACT OF COVID-19 ON THE ASIA PACIFIC LYMPHEDEMA TREATMENT MARKET
9.1 IMPACT ON PRICE
9.2 IMPACT ON DEMAND
9.3 IMPACT ON SUPPLY CHAIN
9.4 STRATEGIC DECISIONS OF GOVERNMENT AND MANUFACTURERS
9.5 CONCLUSION
10 ASIA PACIFIC LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE
10.1 OVERVIEW
10.2 COMPRESSION THERAPY
10.2.1 BY PRODUCT
10.2.1.1 COMPRESSION PUMPS
10.2.1.2 COMPRESSION GARMENTS
10.2.1.2.1 COMPRESSION STOCKINGS
10.2.1.2.2 COMPRESSION SLEEVES
10.2.1.2.3 OTHERS
10.2.1.3 COMPRESSION BANDAGES & WRAPS
10.2.1.4 OTHERS
10.2.2 BY TECHNIQUE
10.2.2.1 STATIC COMPRESSION THERAPY
10.2.2.2 DYNAMIC COMPRESSION THERAPY
10.3 SURGERY
10.3.1 LYMPHOVENOUS TRANSPLANT
10.3.2 LYMPHATICOVENOUS ANASTOMOSIS
10.3.3 LIPOSUCTION
10.3.4 OTHERS
10.4 DRUG THERAPY
10.4.1 NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS)
10.4.2 RETINOIDS
10.4.3 ANTIBIOTICS
10.4.4 OTHERS
10.5 LASER THERAPY
10.6 OTHERS
11 ASIA PACIFIC LYMPHEDEMA TREATMENT MARKET, BY TYPE
11.1 OVERVIEW
11.2 SECONDARY LYMPHEDEMA
11.3 PRIMARY LYMPHEDEMA
11.3.1 LYMPHEDEMA PRAECOX (MEIGE DISEASE)
11.3.2 CONGENITAL LYMPHEDEMA
11.3.3 LYMPHEDEMA TARDA
12 ASIA PACIFIC LYMPHEDEMA TREATMENT MARKET, BY AFFECTED AREA
12.1 OVERVIEW
12.2 LOWER EXTREMITY
12.3 UPPER EXTREMITY
12.4 GENITALIA
13 ASIA PACIFIC LYMPHEDEMA TREATMENT MARKET, BY AGE GROUP
13.1 OVERVIEW
13.2 ADULT
13.3 GERIATRIC
13.4 PEDIATRIC
14 ASIA PACIFIC LYMPHEDEMA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION
14.1 OVERVIEW
14.2 ORAL
14.3 INJECTABLE
14.4 TOPICAL
15 ASIA PACIFIC LYMPHEDEMA TREATMENT MARKET, BY END USER
15.1 OVERVIEW
15.2 HOSPITAL
15.3 SPECIALTY CLINICS
15.4 AMBULATORY SURGICAL CENTERS
15.5 OTHERS
16 ASIA PACIFIC LYMPHEDEMA TREATMENT MARKET, BY DISTRIBUTION CHANNEL
16.1 OVERVIEW
16.2 PHARMACY STORES
16.3 DIRECT TENDER
16.4 OTHERS
17 ASIA PACIFIC LYMPHEDEMA TREATMENT MARKET, BY REGION
17.1 ASIA-PACIFIC
17.1.1 CHINA
17.1.2 JAPAN
17.1.3 INDIA
17.1.4 SOUTH KOREA
17.1.5 AUSTRALIA
17.1.6 INDONESIA
17.1.7 SINGAPORE
17.1.8 PHILIPPINES
17.1.9 THAILAND
17.1.10 MALAYSIA
17.1.11 VIETNAM
17.1.12 REST OF ASIA-PACIFIC
18 ASIA PACIFIC LYMPHEDEMA TREATMENT MARKET: COMPANY LANDSCAPE
18.1 COMPANY SHARE ANALYSIS: ASIA PACIFIC
19 SWOT ANALYIS
20 COMPANY PROFILE
20.1 TACTILE MEDICAL
20.1.1 COMPANY SNAPSHOT
20.1.2 REVENUE ANALYSIS
20.1.3 COMPANY SHARE ANALYSIS
20.1.4 PRODUCT PORTFOLIO
20.1.5 RECENT DEVELOPMENT
20.1.6 CLINICAL TRIAL:
20.2 ESSITY (BSN MEDICAL GMBH)
20.2.1 COMPANY SNAPSHOT
20.2.2 COMPANY SHARE ANALYSIS
20.2.3 PRODUCT PORTFOLIO
20.2.4 RECENT DEVELOPMENT
20.3 3M
20.3.1 COMPANY SNAPSHOT
20.3.2 REVENUE ANALYSIS
20.3.3 COMPANY SHARE ANALYSIS
20.3.4 PRODUCT PORTFOLIO
20.3.5 RECENT DEVELOPMENTS
20.3.6 NEW BUSINESS SEGMENT
20.3.7 ACQUISITION
20.4 CARDINAL HEALTH
20.4.1 COMPANY SNAPSHOT
20.4.2 REVENUE ANALYSIS
20.4.3 COMPANY SHARE ANALYSIS
20.4.4 PRODUCT PORTFOLIO
20.4.5 RECENT DEVELOPMENT
20.5 LOHMANN & RAUSCHER GMBH & CO. KG
20.5.1 COMPANY SNAPSHOT
20.5.2 COMPANY SHARE ANALYSIS
20.5.3 PRODUCT PORTFOLIO
20.5.4 RECENT DEVELOPMENT
20.6 AIROS MEDICAL, INC.
20.6.1 COMPANY SNAPSHOT
20.6.2 PRODUCT PORTFOLIO
20.6.3 RECENT DEVELOPMENT
20.6.4 PRODUCT LAUNCH:
20.7 AVET PHARMACEUTICALS INC.
20.7.1 COMPANY SNAPSHOT
20.7.2 PRODUCT PORTFOLIO
20.7.3 RECENT DEVELOPMENT
20.8 BIOCOMPRESSION SYSTEMS
20.8.1 COMPANY SNAPSHOT
20.8.2 PRODUCT PORTFOLIO
20.8.3 RECENT DEVELOPMENT
20.8.4 AGREEMENT
20.9 CONVATEC INC.
20.9.1 COMPANY SNAPSHOT
20.9.2 PRODUCT PORTFOLIO
20.9.3 RECENT DEVELOPMENT
20.1 HERANTIS PHARMA PLC
20.10.1 COMPANY SNAPSHOT
20.10.2 RECENT DEVELOPMENT
20.11 HUNTLEIGH HEALTHCARE LIMITED
20.11.1 COMPANY SNAPSHOT
20.11.2 PRODUCT PORTFOLIO
20.11.3 RECENT DEVELOPMENT
20.12 JUZO
20.12.1 COMPANY SNAPSHOT
20.12.2 PRODUCT PORTFOLIO
20.12.3 RECENT DEVELOPMENT
20.13 KOYA MEDICAL
20.13.1 COMPANY SNAPSHOT
20.13.2 PRODUCT PORTFOLIO
20.13.3 RECENT DEVELOPMENT
20.13.4 APPROVAL
20.14 MEDI GMBH & CO. KG
20.14.1 COMPANY SNAPSHOT
20.14.2 PRODUCT PORTFOLIO
20.14.3 RECENT DEVELOPMENT
20.15 MEGO AFEK LTD
20.15.1 COMPANY SNAPSHOT
20.15.2 PRODUCT PORTFOLIO
20.15.3 RECENT DEVELOPMENT
20.15.4 APPLICATION LAUNCH:
20.16 PAUL HARTMANN AG
20.16.1 COMPANY SNAPSHOT
20.16.2 REVENUE ANALYSIS
20.16.3 PRODUCT PORTFOLIO
20.16.4 RECENT DEVELOPMENTS
20.17 SANYLEG SRL A SOCIO UNICO
20.17.1 COMPANY SNAPSHOT
20.17.2 PRODUCT PORTFOLIO
20.17.3 RECENT DEVELOPMENT
20.18 SIGVARIS GROUP
20.18.1 COMPANY SNAPSHOT
20.18.2 PRODUCT PORTFOLIO
20.18.3 RECENT DEVELOPMENTS
20.18.4 PRODUCT LAUNCHES:
20.19 SMITH +NEPHEW
20.19.1 COMPANY SNAPSHOT
20.19.2 REVENUE ANALYSIS
20.19.3 PRODUCT PORTFOLIO
20.19.4 RECENT DEVELOPMENT
20.2 THERMOTEK
20.20.1 COMPANY SNAPSHOT
20.20.2 PRODUCT PORTFOLIO
20.20.3 RECENT DEVELOPMENT
21 QUESTIONNAIRE
22 RELATED REPORTS
Liste des tableaux
TABLE 1 PIPELINE ANALYSIS FOR LYMPHEDEMA TREATMENT:
TABLE 2 ASIA PACIFIC LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 3 ASIA PACIFIC COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY REGION 2020-2029 (USD MILLION)
TABLE 4 ASIA PACIFIC COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 5 ASIA PACIFIC COMPRESSION GARMENTS IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 6 ASIA PACIFIC COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TECHNIQUE, 2020-2029 (USD MILLION)
TABLE 7 ASIA PACIFIC SURGERY IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 8 ASIA PACIFIC SURGERY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 9 ASIA PACIFIC DRUG THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 10 ASIA PACIFIC DRUG THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 11 ASIA PACIFIC LASER THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 12 ASIA PACIFIC OTHERS IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 13 ASIA PACIFIC LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 14 ASIA PACIFIC SECONDARY LYMPHEDEMA IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 15 ASIA PACIFIC PRIMARY LYMPHEDEMA IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 16 ASIA PACIFIC PRIMARY LYMPHEDEMA IN LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 17 ASIA PACIFIC LYMPHEDEMA TREATMENT MARKET, BY AFFECTED AREA, 2020-2029 (USD MILLION)
TABLE 18 ASIA PACIFIC LOWER EXTREMITY IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 19 ASIA PACIFIC UPPER EXTREMITY IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 20 ASIA PACIFIC GENITALIA IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 21 ASIA PACIFIC LYMPHEDEMA TREATMENT MARKET, BY AGE GROUP, 2020-2029 (USD MILLION)
TABLE 22 ASIA PACIFIC ADULT IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 23 ASIA PACIFIC GERIATRIC IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 24 ASIA PACIFIC PEDIATRIC IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 25 ASIA PACIFIC LYMPHEDEMA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 26 ASIA PACIFIC ORAL IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 27 ASIA PACIFIC INJECTABLE IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 28 ASIA PACIFIC TOPICAL IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 29 ASIA PACIFIC LYMPHEDEMA TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 30 ASIA PACIFIC HOSPITAL IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 31 ASIA PACIFIC SPECIALITY CLINICS IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 32 ASIA PACIFIC AMBULATORY SURGICAL CENTERS IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 33 ASIA PACIFIC OTHERS IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 34 ASIA PACIFIC LYMPHEDEMA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)
TABLE 35 ASIA PACIFIC PHARMACY STORES IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 36 ASIA PACIFIC DIRECT TENDER IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 37 ASIA PACIFIC OTHERS IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 38 ASIA-PACIFIC LYMPHEDEMA TREATMENT MARKET, BY COUNTRY, 2020-2029 (USD MILLION)
TABLE 39 ASIA-PACIFIC LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 40 ASIA-PACIFIC COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 41 ASIA-PACIFIC COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TECHNIQUE, 2020-2029 (USD MILLION)
TABLE 42 ASIA-PACIFIC COMPRESSION GARMENTS IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 43 ASIA-PACIFIC SURGERY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 44 ASIA-PACIFIC DRUG THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 45 ASIA-PACIFIC LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 46 ASIA-PACIFIC PRIMARY LYMPHEDEMA IN LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 47 ASIA-PACIFIC LYMPHEDEMA TREATMENT MARKET, BY AFFECTED AREA, 2020-2029 (USD MILLION)
TABLE 48 ASIA-PACIFIC LYMPHEDEMA TREATMENT MARKET, BY AGE GROUP, 2020-2029 (USD MILLION)
TABLE 49 ASIA-PACIFIC LYMPHEDEMA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 50 ASIA-PACIFIC LYMPHEDEMA TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 51 ASIA-PACIFIC LYMPHEDEMA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 52 CHINA LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 53 CHINA COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 54 CHINA COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TECHNIQUE, 2020-2029 (USD MILLION)
TABLE 55 CHINA COMPRESSION GARMENTS IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 56 CHINA SURGERY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 57 CHINA DRUG THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 58 CHINA LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 59 CHINA PRIMARY LYMPHEDEMA IN LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 60 CHINA LYMPHEDEMA TREATMENT MARKET, BY AFFECTED AREA, 2020-2029 (USD MILLION)
TABLE 61 CHINA LYMPHEDEMA TREATMENT MARKET, BY AGE GROUP, 2020-2029 (USD MILLION)
TABLE 62 CHINA LYMPHEDEMA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 63 CHINA LYMPHEDEMA TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 64 CHINA LYMPHEDEMA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 65 JAPAN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 66 JAPAN COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 67 JAPAN COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TECHNIQUE, 2020-2029 (USD MILLION)
TABLE 68 JAPAN COMPRESSION GARMENTS IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 69 JAPAN SURGERY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 70 JAPAN DRUG THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 71 JAPAN LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 72 JAPAN PRIMARY LYMPHEDEMA IN LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 73 JAPAN LYMPHEDEMA TREATMENT MARKET, BY AFFECTED AREA, 2020-2029 (USD MILLION)
TABLE 74 JAPAN LYMPHEDEMA TREATMENT MARKET, BY AGE GROUP, 2020-2029 (USD MILLION)
TABLE 75 JAPAN LYMPHEDEMA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 76 JAPAN LYMPHEDEMA TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 77 JAPAN LYMPHEDEMA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 78 INDIA LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 79 INDIA COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 80 INDIA COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TECHNIQUE, 2020-2029 (USD MILLION)
TABLE 81 INDIA SURGERY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 82 INDIA SURGERY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 83 INDIA DRUG THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 84 INDIA LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 85 INDIA PRIMARY LYMPHEDEMA IN LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 86 INDIA LYMPHEDEMA TREATMENT MARKET, BY AFFECTED AREA, 2020-2029 (USD MILLION)
TABLE 87 INDIA LYMPHEDEMA TREATMENT MARKET, BY AGE GROUP, 2020-2029 (USD MILLION)
TABLE 88 INDIA LYMPHEDEMA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 89 INDIA LYMPHEDEMA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 90 INDIA LYMPHEDEMA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 91 SOUTH KOREA LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 92 SOUTH KOREA COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 93 SOUTH KOREA COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TECHNIQUE, 2020-2029 (USD MILLION)
TABLE 94 SOUTH KOREA COMPRESSION GARMENTS IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 95 SOUTH KOREA SURGERY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 96 SOUTH KOREA DRUG THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 97 SOUTH KOREA LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 98 SOUTH KOREA PRIMARY LYMPHEDEMA IN LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 99 SOUTH KOREA LYMPHEDEMA TREATMENT MARKET, BY AFFECTED AREA, 2020-2029 (USD MILLION)
TABLE 100 SOUTH KOREA LYMPHEDEMA TREATMENT MARKET, BY AGE GROUP, 2020-2029 (USD MILLION)
TABLE 101 SOUTH KOREA LYMPHEDEMA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 102 SOUTH KOREA LYMPHEDEMA TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 103 SOUTH KOREA LYMPHEDEMA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 104 AUSTRALIA LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 105 AUSTRALIA COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 106 AUSTRALIA COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TECHNIQUE, 2020-2029 (USD MILLION)
TABLE 107 AUSTRALIA COMPRESSION GARMENTS IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 108 AUSTRALIA SURGERY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 109 AUSTRALIA DRUG THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 110 AUSTRALIA LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 111 AUSTRALIA PRIMARY LYMPHEDEMA IN LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 112 AUSTRALIA LYMPHEDEMA TREATMENT MARKET, BY AFFECTED AREA, 2020-2029 (USD MILLION)
TABLE 113 AUSTRALIA LYMPHEDEMA TREATMENT MARKET, BY AGE GROUP, 2020-2029 (USD MILLION)
TABLE 114 AUSTRALIA LYMPHEDEMA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 115 AUSTRALIA LYMPHEDEMA TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 116 AUSTRALIA LYMPHEDEMA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 117 INDONESIA LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 118 INDONESIA COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 119 INDONESIA COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TECHNIQUE, 2020-2029 (USD MILLION)
TABLE 120 INDONESIA COMPRESSION GARMENTS IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 121 INDONESIA SURGERY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 122 INDONESIA DRUG THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 123 INDONESIA LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 124 INDONESIA PRIMARY LYMPHEDEMA IN LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 125 INDONESIA LYMPHEDEMA TREATMENT MARKET, BY AFFECTED AREA, 2020-2029 (USD MILLION)
TABLE 126 INDONESIA LYMPHEDEMA TREATMENT MARKET, BY AGE GROUP, 2020-2029 (USD MILLION)
TABLE 127 INDONESIA LYMPHEDEMA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 128 INDONESIA LYMPHEDEMA TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 129 INDONESIA LYMPHEDEMA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 130 SINGAPORE LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 131 SINGAPORE COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 132 SINGAPORE COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TECHNIQUE, 2020-2029 (USD MILLION)
TABLE 133 SINGAPORE COMPRESSION GARMENTS IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 134 SINGAPORE SURGERY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 135 SINGAPORE DRUG THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 136 SINGAPORE LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 137 SINGAPORE PRIMARY LYMPHEDEMA IN LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 138 SINGAPORE LYMPHEDEMA TREATMENT MARKET, BY AFFECTED AREA, 2020-2029 (USD MILLION)
TABLE 139 SINGAPORE LYMPHEDEMA TREATMENT MARKET, BY AGE GROUP, 2020-2029 (USD MILLION)
TABLE 140 SINGAPORE LYMPHEDEMA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 141 SINGAPORE LYMPHEDEMA TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 142 SINGAPORE LYMPHEDEMA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 143 PHILIPPINES LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 144 PHILIPPINES COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 145 PHILIPPINES COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TECHNIQUE, 2020-2029 (USD MILLION)
TABLE 146 PHILIPPINES COMPRESSION GARMENTS IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 147 PHILIPPINES SURGERY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 148 PHILIPPINES DRUG THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 149 PHILIPPINES LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 150 PHILIPPINES PRIMARY LYMPHEDEMA IN LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 151 PHILIPPINES LYMPHEDEMA TREATMENT MARKET, BY AFFECTED AREA, 2020-2029 (USD MILLION)
TABLE 152 PHILIPPINES LYMPHEDEMA TREATMENT MARKET, BY AGE GROUP, 2020-2029 (USD MILLION)
TABLE 153 PHILIPPINES LYMPHEDEMA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 154 PHILIPPINES LYMPHEDEMA TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 155 PHILIPPINES LYMPHEDEMA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 156 THAILAND LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 157 THAILAND COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 158 THAILAND COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TECHNIQUE, 2020-2029 (USD MILLION)
TABLE 159 THAILAND COMPRESSION GARMENTS IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 160 THAILAND SURGERY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 161 THAILAND DRUG THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 162 THAILAND LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 163 THAILAND PRIMARY LYMPHEDEMA IN LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 164 THAILAND LYMPHEDEMA TREATMENT MARKET, BY AFFECTED AREA, 2020-2029 (USD MILLION)
TABLE 165 THAILAND LYMPHEDEMA TREATMENT MARKET, BY AGE GROUP, 2020-2029 (USD MILLION)
TABLE 166 THAILAND LYMPHEDEMA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 167 THAILAND LYMPHEDEMA TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 168 THAILAND LYMPHEDEMA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 169 MALAYSIA LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 170 MALAYSIA COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 171 MALAYSIA COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TECHNIQUE, 2020-2029 (USD MILLION)
TABLE 172 MALAYSIA COMPRESSION GARMENTS IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 173 MALAYSIA SURGERY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 174 MALAYSIA DRUG THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 175 MALAYSIA LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 176 MALAYSIA PRIMARY LYMPHEDEMA IN LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 177 MALAYSIA LYMPHEDEMA TREATMENT MARKET, BY AFFECTED AREA, 2020-2029 (USD MILLION)
TABLE 178 MALAYSIA LYMPHEDEMA TREATMENT MARKET, BY AGE GROUP, 2020-2029 (USD MILLION)
TABLE 179 MALAYSIA LYMPHEDEMA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 180 MALAYSIA LYMPHEDEMA TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 181 MALAYSIA LYMPHEDEMA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 182 VIETNAM LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 183 VIETNAM COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 184 VIETNAM COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TECHNIQUE, 2020-2029 (USD MILLION)
TABLE 185 VIETNAM COMPRESSION GARMENTS IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 186 VIETNAM SURGERY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 187 VIETNAM DRUG THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 188 VIETNAM LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 189 VIETNAM PRIMARY LYMPHEDEMA IN LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 190 VIETNAM LYMPHEDEMA TREATMENT MARKET, BY AFFECTED AREA, 2020-2029 (USD MILLION)
TABLE 191 VIETNAM LYMPHEDEMA TREATMENT MARKET, BY AGE GROUP, 2020-2029 (USD MILLION)
TABLE 192 VIETNAM LYMPHEDEMA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 193 VIETNAM LYMPHEDEMA TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 194 VIETNAM LYMPHEDEMA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 195 REST OF ASIA-PACIFIC LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
Liste des figures
FIGURE 1 ASIA PACIFIC LYMPHEDEMA TREATMENT MARKET : SEGMENTATION
FIGURE 2 ASIA PACIFIC LYMPHEDEMA TREATMENT MARKET : DATA TRIANGULATION
FIGURE 3 ASIA PACIFIC LYMPHEDEMA TREATMENT MARKET : DROC ANALYSIS
FIGURE 4 ASIA PACIFIC LYMPHEDEMA TREATMENT MARKET: ASIA PACIFIC VS REGIONAL ANALYSIS
FIGURE 5 ASIA PACIFIC LYMPHEDEMA TREATMENT MARKET : COMPANY RESEARCH ANALYSIS
FIGURE 6 ASIA PACIFIC LYMPHEDEMA TREATMENT MARKET : INTERVIEW DEMOGRAPHICS
FIGURE 7 ASIA PACIFIC LYMPHEDEMA TREATMENT MARKET : DBMR MARKET POSITION GRID
FIGURE 8 ASIA PACIFIC LYMPHEDEMA TREATMENT MARKET : MARKET APPLICATION COVERAGE GRID
FIGURE 9 ASIA PACIFIC LYMPHEDEMA TREATMENT MARKET : VENDOR SHARE ANALYSIS
FIGURE 10 ASIA PACIFIC LYMPHEDEMA TREATMENT MARKET : SEGMENTATION
FIGURE 11 INCREASING PREVALENCE OF LYMPHEDEMA AND RISING HEALTHCARE EXPENDITURE ARE EXPECTED TO DRIVE THE ASIA PACIFIC LYMPHEDEMA TREATMENT MARKET IN THE FORECAST PERIOD OF 2022 TO 2029
FIGURE 12 TREATMENT TYPE SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE ASIA PACIFIC LYMPHEDEMA TREATMENT MARKET IN 2022 & 2029
FIGURE 13 NORTH AMERICA IS EXPECTED TO DOMINATE THE ASIA PACIFIC LYMPHEDEMA TREATMENT MARKET AND ASIA-PACIFIC TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2022 TO 2029
FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF ASIA PACIFIC LYMPHEDEMA TREATMENT MARKET
FIGURE 15 ASIA PACIFIC LYMPHEDEMA TREATMENT MARKET: BY TREATMENT TYPE, 2021
FIGURE 16 ASIA PACIFIC LYMPHEDEMA TREATMENT MARKET: BY TREATMENT TYPE, 2020-2029 (USD MILLION)
FIGURE 17 ASIA PACIFIC LYMPHEDEMA TREATMENT MARKET: BY TREATMENT TYPE, CAGR (2022-2029)
FIGURE 18 ASIA PACIFIC LYMPHEDEMA TREATMENT MARKET: BY TREATMENT TYPE, LIFELINE CURVE
FIGURE 19 ASIA PACIFIC LYMPHEDEMA TREATMENT MARKET: BY TYPE, 2021
FIGURE 20 ASIA PACIFIC LYMPHEDEMA TREATMENT MARKET: BY TYPE, 2020-2029 (USD MILLION)
FIGURE 21 ASIA PACIFIC LYMPHEDEMA TREATMENT MARKET: BY TYPE, CAGR (2022-2029)
FIGURE 22 ASIA PACIFIC LYMPHEDEMA TREATMENT MARKET: BY TYPE, LIFELINE CURVE
FIGURE 23 ASIA PACIFIC LYMPHEDEMA TREATMENT MARKET: BY AFFECTED AREA, 2021
FIGURE 24 ASIA PACIFIC LYMPHEDEMA TREATMENT MARKET: BY AFFECTED AREA, 2020-2029 (USD MILLION)
FIGURE 25 ASIA PACIFIC LYMPHEDEMA TREATMENT MARKET: BY AFFECTED AREA, CAGR (2022-2029)
FIGURE 26 ASIA PACIFIC LYMPHEDEMA TREATMENT MARKET: BY AFFECTED AREA, LIFELINE CURVE
FIGURE 27 ASIA PACIFIC LYMPHEDEMA TREATMENT MARKET: BY AGE GROUP, 2021
FIGURE 28 ASIA PACIFIC LYMPHEDEMA TREATMENT MARKET: BY AGE GROUP, 2020-2029 (USD MILLION)
FIGURE 29 ASIA PACIFIC LYMPHEDEMA TREATMENT MARKET: BY AGE GROUP, CAGR (2022-2029)
FIGURE 30 ASIA PACIFIC LYMPHEDEMA TREATMENT MARKET: BY AGE GROUP, LIFELINE CURVE
FIGURE 31 ASIA PACIFIC LYMPHEDEMA TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2021
FIGURE 32 ASIA PACIFIC LYMPHEDEMA TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
FIGURE 33 ASIA PACIFIC LYMPHEDEMA TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2022-2029)
FIGURE 34 ASIA PACIFIC LYMPHEDEMA TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE
FIGURE 35 ASIA PACIFIC LYMPHEDEMA TREATMENT MARKET: BY END USER, 2021
FIGURE 36 ASIA PACIFIC LYMPHEDEMA TREATMENT MARKET: BY END USER, 2020-2029 (USD MILLION)
FIGURE 37 ASIA PACIFIC LYMPHEDEMA TREATMENT MARKET: BY END USER, CAGR (2022-2029)
FIGURE 38 ASIA PACIFIC LYMPHEDEMA TREATMENT MARKET: BY END USER, LIFELINE CURVE
FIGURE 39 ASIA PACIFIC LYMPHEDEMA TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2021
FIGURE 40 ASIA PACIFIC LYMPHEDEMA TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
FIGURE 41 ASIA PACIFIC LYMPHEDEMA TREATMENT MARKET: BY DISTRIBUTION CHANNEL ,CAGR (2022-2029)
FIGURE 42 ASIA PACIFIC LYMPHEDEMA TREATMENT MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 43 ASIA-PACIFIC LYMPHEDEMA TREATMENT MARKET: SNAPSHOT (2021)
FIGURE 44 ASIA-PACIFIC LYMPHEDEMA TREATMENT MARKET: BY COUNTRY (2021)
FIGURE 45 ASIA-PACIFIC LYMPHEDEMA TREATMENT MARKET: BY COUNTRY (2022 & 2029)
FIGURE 46 ASIA-PACIFIC LYMPHEDEMA TREATMENT MARKET: BY COUNTRY (2021 & 2029)
FIGURE 47 ASIA-PACIFIC LYMPHEDEMA TREATMENT MARKET: BY TREATMENT TYPE (2022-2029)
FIGURE 48 ASIA PACIFIC LYMPHEDEMA TREATMENT MARKET: COMPANY SHARE 2021 (%)
Méthodologie de recherche
La collecte de données et l'analyse de l'année de base sont effectuées à l'aide de modules de collecte de données avec des échantillons de grande taille. L'étape consiste à obtenir des informations sur le marché ou des données connexes via diverses sources et stratégies. Elle comprend l'examen et la planification à l'avance de toutes les données acquises dans le passé. Elle englobe également l'examen des incohérences d'informations observées dans différentes sources d'informations. Les données de marché sont analysées et estimées à l'aide de modèles statistiques et cohérents de marché. De plus, l'analyse des parts de marché et l'analyse des tendances clés sont les principaux facteurs de succès du rapport de marché. Pour en savoir plus, veuillez demander un appel d'analyste ou déposer votre demande.
La méthodologie de recherche clé utilisée par l'équipe de recherche DBMR est la triangulation des données qui implique l'exploration de données, l'analyse de l'impact des variables de données sur le marché et la validation primaire (expert du secteur). Les modèles de données incluent la grille de positionnement des fournisseurs, l'analyse de la chronologie du marché, l'aperçu et le guide du marché, la grille de positionnement des entreprises, l'analyse des brevets, l'analyse des prix, l'analyse des parts de marché des entreprises, les normes de mesure, l'analyse globale par rapport à l'analyse régionale et des parts des fournisseurs. Pour en savoir plus sur la méthodologie de recherche, envoyez une demande pour parler à nos experts du secteur.
Personnalisation disponible
Data Bridge Market Research est un leader de la recherche formative avancée. Nous sommes fiers de fournir à nos clients existants et nouveaux des données et des analyses qui correspondent à leurs objectifs. Le rapport peut être personnalisé pour inclure une analyse des tendances des prix des marques cibles, une compréhension du marché pour d'autres pays (demandez la liste des pays), des données sur les résultats des essais cliniques, une revue de la littérature, une analyse du marché des produits remis à neuf et de la base de produits. L'analyse du marché des concurrents cibles peut être analysée à partir d'une analyse basée sur la technologie jusqu'à des stratégies de portefeuille de marché. Nous pouvons ajouter autant de concurrents que vous le souhaitez, dans le format et le style de données que vous recherchez. Notre équipe d'analystes peut également vous fournir des données sous forme de fichiers Excel bruts, de tableaux croisés dynamiques (Fact book) ou peut vous aider à créer des présentations à partir des ensembles de données disponibles dans le rapport.
